Newsletters
February 13, 2024
February 2024 Newsletter
More News
& publications
Advancing ALS Research Through National Collaboration and Industry Partnership
Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative disease affecting…
Université Laval and Glycovax Pharma Enter into an Exclusive Global LicenseAgreement for the Development of Innovative Galectin-3 Inhibitors
Université Laval and Glycovax Pharma announce an exclusive global license agreement granting…
Stay Compliant for Free: Expert Sexual Harassment Training
Free workplace sexual harassment courses for bio-economy…
